BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 35621632)

  • 21. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
    Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
    J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
    Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ;
    Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.
    Manasanch EE; Salem DA; Yuan CM; Tageja N; Bhutani M; Kwok M; Kazandjian D; Carter G; Steinberg SM; Zuchlinski D; Mulquin M; Calvo K; Maric I; Roschewski M; Korde N; Braylan R; Landgren O; Stetler-Stevenson M
    Leuk Lymphoma; 2015 May; 56(5):1416-24. PubMed ID: 25263319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies.
    Hagos YB; Lecat CSY; Patel D; Mikolajczak A; Castillo SP; Lyon EJ; Foster K; Tran TA; Lee LSH; Rodriguez-Justo M; Yong KL; Yuan Y
    Cancer Res; 2024 Feb; 84(3):493-508. PubMed ID: 37963212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
    Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
    Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.
    Ioannou MG; Stathakis E; Lazaris AC; Papathomas T; Tsiambas E; Koukoulis GK
    Pathol Oncol Res; 2009 Mar; 15(1):25-9. PubMed ID: 18553158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma.
    Malherbe JAJ; Fuller KA; Mirzai B; Augustson BM; Erber WN
    J Clin Pathol; 2022 Jan; 75(1):50-57. PubMed ID: 33234694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
    Morgan TK; Zhao S; Chang KL; Haddix TL; Domanay E; Cornbleet PJ; Arber DA; Natkunam Y
    Am J Clin Pathol; 2006 Oct; 126(4):545-51. PubMed ID: 16938662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
    Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
    Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
    Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
    Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma.
    Billadeau D; Van Ness B; Kimlinger T; Kyle RA; Therneau TM; Greipp PR; Witzig TE
    Blood; 1996 Jul; 88(1):289-96. PubMed ID: 8704185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
    Kim D; Park CY; Medeiros BC; Weissman IL
    Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements.
    Bergsagel PL; Masellis Smith A; Belch AR; Pilarski LM
    Curr Top Microbiol Immunol; 1995; 194():17-24. PubMed ID: 7534667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
    Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
    Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation stage of myeloma plasma cells: biological and clinical significance.
    Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
    Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
    Gupta L; Suku P; Dash A; Bose P; Sharma P; Mallik N; Sreedharanunni S; Varma N; Jandial A; Malhotra P; Sachdeva MUS
    Curr Probl Cancer; 2024 Feb; 48():101025. PubMed ID: 37951052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma.
    Zhang L; Beasley S; Prigozhina NL; Higgins R; Ikeda S; Lee FY; Marrinucci D; Jia S
    J Circ Biomark; 2016; 5():10. PubMed ID: 28936258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
    Qasaimeh MA; Wu YC; Bose S; Menachery A; Talluri S; Gonzalez G; Fulciniti M; Karp JM; Prabhala RH; Karnik R
    Sci Rep; 2017 Apr; 7():45681. PubMed ID: 28374831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.